List of Excipients in Branded Drug IBANDRONATE SODIUM

Generic Drugs Containing IBANDRONATE SODIUM

Company	Ingredient	NDC	Excipient
Accord Healthcare Inc	ibandronate sodium	16729-274	ACETIC ACID
Accord Healthcare Inc	ibandronate sodium	16729-274	SODIUM ACETATE
Accord Healthcare Inc	ibandronate sodium	16729-274	SODIUM CHLORIDE
Accord Healthcare Inc	ibandronate sodium	16729-274	WATER
Sagent Pharmaceuticals	ibandronate sodium	25021-827	ACETIC ACID

What are the Most Frequently-Used Excipients in IBANDRONATE SODIUM?

# Of NDCs	Excipient
7	ACETIC ACID
2	AMMONIA
8	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
8	CROSPOVIDONE

Ibandronate Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Ibandronate sodium is a genericized bisphosphonate with two established dosage forms: a once-monthly oral tablet and an intravenous injection administered every three months. The largest excipient opportunities are in oral tolerability, dose administration, stability, packaging, and differentiated delivery rather than in conventional reformulation alone. The commercial market is mature, but manufacturers can still compete through reliable generic supply, lower excipient risk, adherence-oriented presentations, hospital-ready injection products, and niche formulations for patients who cannot tolerate oral bisphosphonates.

What is the FDA status of ibandronate sodium?

Ibandronate sodium is approved for the treatment and prevention of postmenopausal osteoporosis. In the United States, the reference product is Boniva, marketed by Genentech, a member of the Roche Group. FDA-approved dosage forms include:

Dosage form	Strength	Administration	Principal market use
Oral tablet	150 mg	Once monthly, at least 60 minutes before food or beverages other than water	Postmenopausal osteoporosis
Intravenous injection	3 mg/3 mL	Once every three months	Postmenopausal osteoporosis

The oral tablet must be taken with plain water while the patient is sitting or standing. The patient must remain upright and avoid food, beverages, and other medicines for at least 60 minutes. These restrictions are linked to the low and variable oral bioavailability of bisphosphonates and their interaction with polyvalent cations.[1]

The injection is administered intravenously by a health professional. It is not interchangeable with oral dosing on a milligram-for-milligram basis.

FDA-approved generic ibandronate sodium tablets and injections are available. Because ibandronate is a small molecule, biosimilar regulation does not apply. Competitive products proceed through the abbreviated new drug application pathway rather than the biosimilar pathway.[2]

What excipients are used in ibandronate sodium products?

The exact excipient profile depends on the manufacturer, dosage form, strength, and market. Oral tablets generally use conventional direct-compression or granulation excipients. Injectable products require a narrower excipient set because of intravenous safety, solution stability, particulate control, and compatibility requirements.

Oral tablet excipient classes

Typical oral ibandronate tablet formulations may include:

Excipient class	Common examples	Primary function
Diluent	Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Tablet mass and compressibility
Binder	Povidone, copovidone, hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Tablet breakup and dissolution
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Manufacturing performance
Glidant	Colloidal silicon dioxide, talc	Powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protection, swallowability, identification

The principal excipient strategy is to achieve rapid tablet disintegration and reproducible dissolution while avoiding a formulation that increases cation-related binding or creates administration confusion. Calcium, magnesium, iron and aluminum are clinically relevant because they can reduce bisphosphonate absorption when administered together.[1]

Injectable excipient classes

Ibandronate sodium injection is an aqueous intravenous product. Injectable formulations generally require:

• Water for injection.
• pH adjustment agents.
• A controlled ionic environment.
• Tightly controlled levels of degradation products and particulates.
• Container-closure systems compatible with the solution.

The formulation must not be mixed with calcium-containing solutions. The FDA label specifically warns against administration with calcium-containing intravenous solutions because of compatibility and precipitation concerns.[1]

An injectable ibandronate product should be assessed for:

• pH drift during shelf life.
• Container interaction.
• Subvisible particles.
• Extractables and leachables.
• Compatibility with infusion and injection equipment.
• Sterility assurance.
• Terminal sterilization or aseptic-processing requirements.
• Stability after removal from the primary package.

What excipient strategy best supports oral ibandronate tablets?

The strongest oral strategy is conservative excipient selection combined with robust dissolution and clear administration controls.

1. Minimize cation-related risk

Formulators should avoid unnecessary use of calcium-, magnesium-, aluminum-, or iron-containing excipients where equivalent alternatives are available. Dibasic calcium phosphate may be technically useful as a diluent, but it creates a more complicated interaction and risk-assessment profile for a drug whose absorption is already highly sensitive to polyvalent cations.

Mannitol, microcrystalline cellulose, lactose, and compatible polymeric binders can provide alternative tablet-mass and compression functionality. The final formulation must be evaluated through comparative dissolution, assay, content uniformity, and stability studies.

2. Optimize disintegration without increasing friability

Monthly 150 mg tablets are relatively large compared with many daily oral drugs. A formulation that disintegrates rapidly can improve dissolution consistency and reduce the risk that slow tablet breakup contributes to variable exposure.

Crospovidone and croscarmellose sodium are standard candidates. Their use should be balanced against tablet hardness, friability, moisture sensitivity, and manufacturing scale-up. Excessive lubricant levels, especially magnesium stearate, can retard wetting and dissolution.

3. Improve swallowability

Film coating can reduce the perception of tablet roughness and improve handling. A thinner hypromellose-based coating may reduce tablet size and coating-cycle time. Colorants can support product identification, but titanium dioxide and iron oxide choices may affect market access in jurisdictions with changing excipient policies.

A commercial opportunity exists for smaller, smoother, clearly marked tablets that reduce patient confusion without changing the active dose or dosing interval.

4. Control moisture and chemical stability

Bisphosphonate formulations should be assessed for moisture uptake, polymorphic behavior, and interaction with packaging components. A high-barrier blister or bottle with a desiccant may be appropriate depending on the formulation and stability data.

Unit-dose blister packaging has a second commercial benefit: it can reinforce the monthly schedule and reduce dispensing errors. Calendarized packaging can be more valuable than adding a novel excipient with limited clinical benefit.

What formulation patents could protect ibandronate sodium products?

The original composition-of-matter and pharmaceutical development patents for ibandronate are expired or no longer provide a meaningful barrier to routine generic entry in the United States. Current protection is more likely to arise from formulation, manufacturing, packaging, delivery, or method-of-use claims than from the active ingredient itself.

Potential patentable subject matter includes:

Technology area	Possible claim focus	Commercial strength
Oral formulation	Specific excipient ratios, dissolution profile, tablet architecture	Low to moderate unless clinically differentiated
Modified release	Delayed or controlled release to reduce upper-GI exposure	Moderate, but development risk is high
Effervescent or dispersible product	Administration in water with controlled dosing	Moderate
Gastroretentive delivery	Extended gastric residence and exposure control	High technical risk
Injectable product	pH, container, stability, particulate-control process	Moderate
Prefilled syringe	Device, closure, needle, and administration system	Moderate
Packaging	Calendar blister, adherence packaging, dose-protection system	Low to moderate
Manufacturing	Crystallization, granulation, sterilization, impurity control	Moderate to high if difficult to design around

A formulation patent is strongest when it claims a measurable technical effect, such as improved stability, lower impurity formation, a specific dissolution profile, reduced injection particles, or improved compatibility. A patent that merely substitutes one conventional filler for another is more vulnerable to obviousness and lack-of-technical-effect challenges.

When does ibandronate sodium lose exclusivity?

Ibandronate sodium has already lost the core exclusivity that protected the branded product from ordinary generic competition. Boniva tablets and injections now face generic competition in the United States.

The key exclusivity categories are:

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired
Composition-of-matter patent protection	Expired or no longer a practical barrier to standard generics
Oral formulation patents	Requires product-specific Orange Book review
Injection formulation patents	Requires product-specific Orange Book review
Method-of-use patents	May remain relevant only if listed, unexpired, and enforceable
Pediatric exclusivity	No significant current barrier to generic supply
Biosimilar exclusivity	Not applicable

Patent expiration dates must be verified against the current FDA Orange Book and USPTO records for each listed patent, because listed patents can differ by dosage form and reference product.[3] The commercial point is clear: routine ibandronate sodium generic entry is established, while new investment must rely on product differentiation rather than basic active-ingredient exclusivity.

What is the Orange Book status of ibandronate sodium?

The FDA Orange Book identifies approved reference products, therapeutic-equivalence information, and patents or exclusivities associated with listed drugs. Ibandronate sodium tablets and injections should be evaluated separately because dosage-form-specific patents and certifications may differ.

For a prospective generic or reformulated product, the relevant Orange Book review should cover:

1. Reference-listed drug designation.
2. Therapeutic-equivalence code.
3. Listed patent numbers.
4. Patent expiration dates.
5. Pediatric exclusivity blocks.
6. Whether a Paragraph IV certification has been filed.
7. Whether any listed patent has been delisted or disclaimed.

FDA-approved generic products generally use an ANDA and must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. A formulation that changes excipients may still qualify as a generic if it satisfies the relevant FDA requirements and does not create safety, efficacy, or bioequivalence concerns.[2]

Which companies are challenging or competing with Boniva?

The competitive field includes generic manufacturers supplying oral tablets and injectable products. Publicly visible competitors have included large generic manufacturers and specialty suppliers, although market participation varies by procurement contract, shortage conditions, wholesaler stocking, and reimbursement.

The competitive structure is:

Segment	Competitive basis
Oral generic tablets	Lowest acquisition cost, reliable supply, therapeutic equivalence
Generic injection	Sterile manufacturing, hospital contracts, low particulate burden, supply continuity
Branded Boniva	Brand recognition and historical physician familiarity
Other osteoporosis drugs	Clinical differentiation, dosing frequency, fracture data, renal restrictions
Specialty delivery products	Administration convenience and adherence support

Ibandronate competes clinically with alendronate, risedronate, zoledronic acid, denosumab, raloxifene, and anabolic or bone-forming therapies. Ibandronate’s monthly oral and quarterly intravenous schedules are commercially useful, but its fracture-outcome profile and administration restrictions affect positioning.

What commercial opportunities exist for ibandronate sodium excipients?

Monthly adherence packaging

A unit-dose monthly blister with calendar labeling can reduce missed-dose risk. The opportunity is strongest in retail pharmacy, Medicare populations, and specialty osteoporosis programs.

Lower-interaction oral formulation

A formulation that eliminates unnecessary mineral excipients and provides consistent dissolution could support a quality-focused generic strategy. The claim should rely on documented performance, not on excipient novelty alone.

Smaller or easier-to-swallow tablets

Tablet engineering, film coating, and compression optimization may improve patient acceptance. A smaller tablet may be commercially valuable even if the active dose remains unchanged.

Oral dosage forms for swallowing difficulty

Dispersible, orally disintegrating, or liquid formulations could target patients unable to swallow conventional tablets. The principal obstacles are taste, dosing accuracy, absorption variability, and the need to preserve the 60-minute administration restrictions.

Preservative-free prefilled injection

A ready-to-administer syringe may reduce preparation steps and medication errors. Its value depends on device compatibility, terminal sterility strategy, stability, and hospital purchasing requirements.

Contract manufacturing and regional supply

Ibandronate injection requires sterile capacity, analytical controls, and validated container-closure systems. Manufacturers with underused sterile-filling lines may find contract or private-label opportunities, especially where supply reliability matters more than brand differentiation.

What generic launch risks exist for ibandronate sodium?

The principal risks are regulatory and operational rather than basic active-ingredient patent barriers.

Risk	Impact
Dissolution variability	Bioequivalence or quality failure
Cation-containing excipients	Absorption and labeling concerns
Moisture sensitivity	Shelf-life failure
Large tablet size	Adherence and complaint risk
Injectable particulates	Batch rejection or regulatory action
Calcium-containing diluent incompatibility	Administration safety risk
Sterile manufacturing failure	Product shortage or recall
Low generic margins	Limited return on formulation investment
Small market size	Weak scale economics
Competing osteoporosis therapies	Price and volume pressure

Paragraph IV challenges may remain relevant if an unexpired listed patent applies to a specific reference product or dosage form. However, standard generic competition is more likely to proceed through Paragraph III or a certification that no relevant patent blocks approval, depending on the current Orange Book record.[3]

How strong is the ibandronate sodium patent estate?

The core patent estate is weak for blocking ordinary generic tablets and injections because the active ingredient has long been commercially established and generic products are approved. The remaining patent opportunity is narrower.

A practical strength assessment is:

Estate component	Strength
Active ingredient	Low
Basic tablet composition	Low
Conventional excipient substitution	Low
Demonstrated stability improvement	Moderate
Novel delivery system	Moderate to high, with development risk
Prefilled injection device	Moderate
Sterile manufacturing process	Moderate if difficult to reproduce
Method of use	Product- and claim-specific

Patent value is highest where the formulation produces a clinically or operationally meaningful result and where a competitor cannot easily substitute another excipient system without losing that result.

What licensing deals affect ibandronate sodium?

No major publicly documented excipient-specific licensing transaction defines the ibandronate sodium market. The branded product originated from Roche/Genentech development and commercialization activity, while generic competition is generally supplied through independent ANDA holders, distributors, and contract manufacturers.

Potential transaction structures include:

• ANDA acquisition or licensing.
• Regional commercialization rights.
• Sterile-fill manufacturing agreements.
• Private-label supply contracts.
• Device co-development for prefilled syringes.
• Packaging and adherence-program partnerships.
• Licensing of a differentiated oral delivery platform.

For a buyer, the most valuable diligence points are approved manufacturing sites, current FDA inspection history, annual production capacity, product-specific stability data, litigation status, and customer concentration.

How does ibandronate sodium compare with competing bisphosphonates?

Product	Typical schedule	Administration burden	Excipient opportunity
Ibandronate oral	Monthly	60-minute fasting and upright requirements	Smaller tablet, adherence packaging, dissolution control
Ibandronate injection	Quarterly	Healthcare administration and IV compatibility controls	Prefilled syringe, stability, sterile supply
Alendronate	Daily or weekly	Similar fasting and upright restrictions	Low-cost tablets and alternate oral presentations
Risedronate	Daily, weekly, or monthly depending on product	Food and administration restrictions	Dose-calendar packaging and tolerability
Zoledronic acid	Annual IV infusion	Infusion-center administration	Infusion compatibility and ready-to-use presentation
Denosumab	Six-month injection	Biologic storage and administration	Not an excipient-based generic opportunity

Ibandronate’s differentiation is the combination of monthly oral dosing and quarterly injection dosing. Its limitations are administration complexity for tablets and a narrower fracture-evidence profile than some competing therapies.

Key Takeaways

• Ibandronate sodium is a mature small-molecule market with established generic competition.
• The main excipient risks involve polyvalent cations, dissolution variability, moisture stability, and injectable compatibility.
• Calcium-, magnesium-, iron-, and aluminum-containing excipients require careful justification in oral products.
• Oral commercial opportunities include smaller tablets, improved film coating, rapid disintegration, calendar blister packs, and clearer monthly dosing support.
• Injectable opportunities include preservative-free presentations, prefilled syringes, container-closure optimization, and reliable sterile supply.
• The core active-ingredient patent barrier is no longer commercially strong.
• Formulation patents are more defensible when supported by measurable stability, dissolution, particulate, or administration benefits.
• Ibandronate has no biosimilar pathway because it is a small molecule.
• The strongest near-term business case is operational differentiation in generic supply, packaging, sterile manufacturing, and patient adherence.

FAQs

Can calcium phosphate be used as an excipient in ibandronate tablets?

It may be technically possible, but calcium-containing excipients require a specific interaction and bioequivalence assessment because calcium can reduce bisphosphonate absorption. Non-mineral diluents may provide a lower-risk formulation path.

Can ibandronate sodium be formulated as an orally disintegrating tablet?

Potentially, but the product would still need to preserve dose accuracy, bioequivalence, palatability, stability, and the required fasting and upright administration instructions.

Can ibandronate injection be mixed with saline?

Compatibility depends on the approved product and administration instructions. Calcium-containing intravenous solutions must be avoided. Product-specific labeling and compatibility data control the permitted diluent and administration method.[1]

Is a new ibandronate formulation eligible for three-year FDA exclusivity?

A new formulation may qualify for regulatory exclusivity only if it meets the statutory requirements and contains a sufficient change supported by new clinical investigations. A conventional excipient substitution alone is unlikely to create meaningful exclusivity.

What is the most attractive commercial formulation opportunity?

A monthly oral tablet with improved swallowability and calendarized unit-dose packaging offers the lowest development risk. A prefilled quarterly injection offers greater operational differentiation but requires sterile manufacturing, device, stability, and container-closure investment.

References

1. U.S. Food and Drug Administration. (2023). Boniva (ibandronate sodium) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Generics.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2016). Inactive ingredient database.
5. National Library of Medicine. (n.d.). DailyMed: Ibandronate sodium tablet and injection labeling.